This information is intended for use by health professionals

1. Name of the medicinal product

Oilatum Junior

2. Qualitative and quantitative composition

Light Liquid paraffin BP 63.4% w/w.

3. Pharmaceutical form

Liquid bath additive.

4. Clinical particulars
4.1 Therapeutic indications

Oilatum Junior is indicated in the treatment of contact dermatitis, atopic dermatitis, senile pruritus, ichthyosis and related dry skin conditions.

Route of administration: Topical

4.2 Posology and method of administration

Oilatum Junior may be used as frequently as necessary. Oilatum Junior should always be used with water, either added to the water or applied to wet skin.

For adults add 1-3 capfuls to an 8 inch bath of water. Soak for 10-20 minutes. Pat dry.

For infants, add ½-2 capfuls to a basin of water. Apply gently over entire body with a sponge. Pat dry.

4.3 Contraindications

None.

4.4 Special warnings and precautions for use

Patients should be advised to use care to avoid slipping in the bath. If a rash or skin irritation should occur, stop using the product and consult your doctor.

Oilatum Junior should be used with caution in patients with a known sensitivity or allergy to light liquid paraffin (LLP) or to any of the excipients in the preparation.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Pregnancy and lactation

Fertility

There are no data on the use of Oilatum Junior on human fertility.

Pregnancy

No effects during pregnancy are anticipated, since systemic exposure to Oilatum Junior is expected to be low.

Lactation

It is not known if Oilatum Junior is excreted in human milk. Risk to the infant is likely to be low since systemic exposure is low. Patients should be advised to ensure that any residual product is fully washed off the breast prior to breast-feeding.

4.7 Effects on ability to drive and use machines

None.

4.8 Undesirable effects

Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1,000 and < 1/100), rare (≥1/10, 000 and <1/1,000); very rare (<1/10, 000) and not known (cannot be estimated from the available data).

Post-marketing data

Skin and Subcutaneous Tissue Disorders

Rare: Application site reactions including application site irritation, rash, erythema, pruritus

Immune System Disorders

Rare: Application site hypersensitivity reactions including application site dermatitis

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:www.mhra.gov.uk/yellowcard.

4.9 Overdose

Symptoms and signs

The product is intended for cutaneous use only. Accidental ingestion may cause gastrointestinal irritation with nausea, vomiting and diarrhoea.

Treatment

In case of accidental ingestion, management should be as clinically indicated or as recommended by the national poisons centre, where available.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Light liquid paraffin exerts an emollient effect by forming an occlusive oil film on the stratum corneum. This prevents excessive evaporation of water from the skin surface and aids in the prevention of dryness.

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

None.

6. Pharmaceutical particulars
6.1 List of excipients

Acetylated Lanolin Alcohols

Isopropyl Palmitate

Polyethylene Glycol 400 dilaurate

Macrogol ester.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

For the product as packaged for sale: 5 years.

6.4 Special precautions for storage

None.

6.5 Nature and contents of container

High density polyethylene bottles with a screw cap. Capacity: 25ml, 150ml, 200ml, 250ml, 300ml, 350ml, 400ml, 500ml, 600ml, 1000ml.

6.6 Special precautions for disposal and other handling

There are no special instructions for use or handling of Oilatum Junior.

7. Marketing authorisation holder

GlaxoSmithKline Consumer Healthcare (UK) Trading Limited,

trading as

Stiefel

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

8. Marketing authorisation number(s)

PL 44673/0030

9. Date of first authorisation/renewal of the authorisation

June 1993.

10. Date of revision of the text

27th April 2016